Purpose: The objective is to update previous meta-analyses with a systematic review of randomized palliative radiotherapy (RT) trials comparing single fractions (SFs) versus multiple fractions (MFs). Methods: The analysis includes all published reports from randomized trials comparing SF or MF schedules for the treatment of painful bone metastases with localized RT. A systematic review was performed using the random-effects model with Review Manager version 4.1 (Cochrane Collaboration, Oxford, UK). The odds ratio and 95% CI were calculated for each trial and presented in a forest plot. Results: A total of 16 randomized trials from 1986 onward were identified. For intention-to-treat patients, the overall response (OR) rates for pain were similar for SF at 1,468 (58%) of 2,513 patients and MF RT at 1,466 (59%) of 2,487 patients. The complete response (CR) rates for pain were 23% (545 of 2,375 patients) for SF and 24% (558 of 2,351 patients) for MF RT. No significant differences were found in response rates. Trends showing an increased risk for SF RT arm patients in terms of pathological fractures and spinal cord compressions were observed, but neither were statistically significant (P = .75 and P = .13, respectively). The likelihood of re-treatment was 2.5-fold higher (95% CI, 1.76 to 3.56) in SF RT arm patients (P < .00001). Repeated analysis of these end points, excluding dropout patients, did not alter the conclusions. Generally, no significant differences with respect to acute toxicities were observed between the arms. Conclusion: No significant differences in the arms were observed for overall and CR rates in both intention-to-treat and assessable patients. However, a significantly higher re-treatment rate with SFs was evident.

Cancer patients often experience multiple symptoms, and those symptoms can independently predict changes in patient function, treatment failures, and post-therapeutic outcomes. Symptom clusters are defined as two or more concurrent symptoms that are related and may or may not have a common cause. The purpose of the present study was to review, in cancer patients, common symptom clusters and their predictors. Using medline, embase, Cochrane Central, and cinahl, we conducted a literature search on symptom clusters in cancer patients. Studies that investigated predetermined clusters were not included. We identified seven individual studies and one group of five studies validating the M.D. Anderson Symptom Inventory. These studies had been published between 1997 and 2006. Two of the seven individual studies and the group of five studies that had validated the M.D. Anderson Symptom Inventory included patients with any cancer type; three studies included breast cancer patients only; and two studies included lung cancer patients only. A gastrointestinal cluster consisting of nausea and vomiting was the single cluster common to two of the studies. The severity of this cluster increased when patients were treated with chemotherapy. No common clusters were found in the lung and breast cancer patient populations. However, breast cancer patients experienced more symptom cluster involvement while undergoing chemotherapy. We noted methodology disparities among the papers with regard to assessment tools used, statistical analyses, and populations. Research on symptom clusters is still in an early stage. Multiple symptoms clearly affect prognosis, quality of life, and functional status. The study of symptom clusters is important for its implications regarding patient management, and a consensus on appropriate research methodology is vital.